A third COVID-19 vaccine shot which will be administered six to twelve months after the two dose regimen of the patient is set to be trialed by Pfizer. According to Pfizer and BioNtech, with this trial, the two companies will examine if a booster shot of the vaccine will help tackle any new emerging strains of the virus. Participants from the Phase 1 trial in the US will be used for the study.
🤢🤢🤢🤢